Validation and Characterization of MiXeno™ Humanized Mouse Models for Immuno-Oncology
Lan Zhang, Juan Zhan, Meng Qiao, Xuefei Yan, Jian Ding, Fei Chen, Xiaoyu An, WenQing Yang, and Qian Shi
Despite the unprecedented success of immune checkpoint antibodies for a variety of cancer types, a lack of immunocompetent preclinical mouse models remains a major challenge for the development of novel immunotherapeutics.
Different strategies to humanize immunodeficient mouse model systems have been reported, including replenishment with human HSC or PBMC, as well as the development of chimeric models harboring human immune checkpoint targets in immunocompetent mice.
CrownBio has successfully established a number of human PBMC-humanized xenograft models (MiXeno), which require optimization.
Read this Poster to Discover:
- Available MiXeno models and their broad spectrum of applications in IO including the evaluation of human specific immuno-modulatory drugs in vivo
- Optimization of MiXeno models including inoculation protocols for administration of both immune and cancer cells
- That MiXeno provides a rapid and simple humanization strategy, and is a proven and valid alternative to other humanized mouse models